

Stian Knappskog

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4384331/publications.pdf>

Version: 2024-02-01

97
papers

14,623
citations

147801

31
h-index

46799

89
g-index

105
all docs

105
docs citations

105
times ranked

28749
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421. | 27.8 | 8,060 |
| 2 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54. | 27.8 | 1,760 |
| 3 | Subclonal diversification of primary breast cancer revealed by multiregion sequencing. <i>Nature Medicine</i> , 2015, 21, 751-759. | 30.7 | 711 |
| 4 | Genomic Evolution of Breast Cancer Metastasis and Relapse. <i>Cancer Cell</i> , 2017, 32, 169-184.e7. | 16.8 | 534 |
| 5 | Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251-1253. | 12.6 | 348 |
| 6 | Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track – Letter. <i>Cancer Research</i> , 2010, 70, 6393-6396. | 0.9 | 278 |
| 7 | Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. <i>Nature Genetics</i> , 2014, 46, 487-491. | 21.4 | 254 |
| 8 | Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. <i>Clinical Cancer Research</i> , 2010, 16, 3356-3367. | 7.0 | 235 |
| 9 | Clinical effect of temozolomide–based chemotherapy in poorly differentiated endocrine carcinoma after progression on first–line chemotherapy. <i>Cancer</i> , 2011, 117, 4617-4622. | 4.1 | 233 |
| 10 | Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718. | 27.8 | 229 |
| 11 | The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. <i>Cancer Cell</i> , 2011, 19, 273-282. | 16.8 | 104 |
| 12 | The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019, 29, 356-366. | 5.5 | 85 |
| 13 | The level of synthesis and secretion of <i>Gussia princeps</i> luciferase in transfected CHO cells is heavily dependent on the choice of signal peptide. <i>Journal of Biotechnology</i> , 2007, 128, 705-715. | 3.8 | 84 |
| 14 | Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016, 139, 647-656. | 5.1 | 79 |
| 15 | EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. <i>Neuro-Oncology</i> , 2016, 18, 1644-1655. | 1.2 | 78 |
| 16 | CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer. <i>PLoS ONE</i> , 2008, 3, e3062. | 2.5 | 74 |
| 17 | Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824. | 5.5 | 69 |
| 18 | Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. <i>PLoS ONE</i> , 2011, 6, e19249. | 2.5 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. <i>PLoS Genetics</i> , 2016, 12, e1006225. | 3.5 | 64 |
| 20 | The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2022, 29, 1-14. | 3.1 | 62 |
| 21 | Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. <i>Clinical Cancer Research</i> , 2011, 17, 4948-4958. | 7.0 | 58 |
| 22 | Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R47. | 5.0 | 58 |
| 23 | P53 and its molecular basis to chemoresistance in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S23-S30. | 3.4 | 57 |
| 24 | Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer & Metabolism</i> , 2019, 7, 6. | 5.0 | 51 |
| 25 | SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. <i>European Journal of Cancer</i> , 2012, 48, 1988-1996. | 2.8 | 43 |
| 26 | APOBEC3A/B deletion polymorphism and cancer risk. <i>Carcinogenesis</i> , 2018, 39, 118-124. | 2.8 | 39 |
| 27 | MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk. <i>Oncotarget</i> , 2011, 2, 251-258. | 1.8 | 39 |
| 28 | Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. <i>Tumor Biology</i> , 2015, 36, 1003-1013. | 1.8 | 37 |
| 29 | White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018, 168, 326. | 3.9 | 37 |
| 30 | Effects of the <i>MDM2</i> promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. <i>Transcription</i> , 2011, 2, 207-210. | 3.1 | 34 |
| 31 | Outcome after surgery for primary hyperaldosteronism may depend on <i>KCNJ5</i> tumor mutation status: a population-based study from Western Norway. <i>Langenbeck's Archives of Surgery</i> , 2013, 398, 869-874. | 1.9 | 34 |
| 32 | MDM4 SNP34091 (rs4245739) and its effect on breast, colon, lung, and prostate cancer risk. <i>Cancer Medicine</i> , 2015, 4, 1901-1907. | 2.8 | 33 |
| 33 | Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4235. | 4.1 | 32 |
| 34 | Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. <i>Molecular Cancer</i> , 2010, 9, 173. | 19.2 | 29 |
| 35 | Influence of <i>MDM2</i> SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. <i>International Journal of Cancer</i> , 2015, 137, 96-103. | 5.1 | 27 |
| 36 | ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. <i>Scientific Reports</i> , 2019, 9, 17471. | 3.3 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Concomitant inactivation of the p53 and pRB functional pathways predicts resistance to DNA damaging drugs in breast cancer <i>in vivo</i> . <i>Molecular Oncology</i> , 2015, 9, 1553-1564. | 4.6 | 23 |
| 38 | A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 1155-1163. | 2.8 | 22 |
| 39 | Constitutional Mosaic Epimutations – a hidden cause of cancer?. <i>Cell Stress</i> , 2019, 3, 118-135. | 3.2 | 22 |
| 40 | Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). <i>Oncotarget</i> , 2014, 5, 8223-8234. | 1.8 | 22 |
| 41 | Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. <i>Oncotarget</i> , 2016, 7, 28637-28646. | 1.8 | 22 |
| 42 | The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian but not endometrial cancer. <i>Tumor Biology</i> , 2016, 37, 10697-10702. | 1.8 | 20 |
| 43 | Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines. <i>Cell Death Discovery</i> , 2017, 3, 17026. | 4.7 | 20 |
| 44 | CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia. <i>Oncotarget</i> , 2013, 4, 1438-1448. | 1.8 | 20 |
| 45 | Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers. <i>Scientific Reports</i> , 2019, 9, 5244. | 3.3 | 19 |
| 46 | Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 11. | 2.6 | 18 |
| 47 | Mutations and polymorphisms of the p21B transcript in breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 908-910. | 5.1 | 16 |
| 48 | Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 867-876. | 3.3 | 16 |
| 49 | Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue. <i>PLoS ONE</i> , 2013, 8, e74618. | 2.5 | 16 |
| 50 | High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 177-190. | 2.5 | 16 |
| 51 | Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. <i>Oncotarget</i> , 2017, 8, 41227-41241. | 1.8 | 16 |
| 52 | C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. <i>Nature Communications</i> , 2022, 13, 69. | 12.8 | 16 |
| 53 | The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6000-6004. | 7.0 | 15 |
| 54 | Effect of CYP19 rs6493497 and rs7176005 haplotype status on <i>in vivo</i> aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 128, 69-75. | 2.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | High expression of the p53 isoform \hat{I}^3 is associated with reduced progression-free survival in uterine serous carcinoma. <i>BMC Cancer</i> , 2018, 18, 684. | 2.6 | 15 |
| 56 | <i>TP53</i> status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. <i>Acta Oncologica</i> , 2014, 53, 1347-1355. | 1.8 | 14 |
| 57 | MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. <i>BMC Cancer</i> , 2017, 17, 97. | 2.6 | 14 |
| 58 | Alterations of the retinoblastoma gene in metastatic breast cancer. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 319-326. | 3.3 | 13 |
| 59 | Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. <i>European Journal of Endocrinology</i> , 2012, 166, 941-949. | 3.7 | 13 |
| 60 | MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. <i>PLoS ONE</i> , 2012, 7, e36263. | 2.5 | 12 |
| 61 | Tumor cells interact with red blood cells via galectin-4 - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 401-409. | 4.4 | 11 |
| 62 | Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. <i>BMC Cell Biology</i> , 2017, 18, 17. | 3.0 | 11 |
| 63 | Assessment of tumor suppressor promoter methylation in healthy individuals. <i>Clinical Epigenetics</i> , 2020, 12, 131. | 4.1 | 11 |
| 64 | DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. <i>Breast Cancer Research</i> , 2022, 24, . | 5.0 | 11 |
| 65 | Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2514-2516. | 0.7 | 10 |
| 66 | Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. <i>BMC Cancer</i> , 2012, 12, 454. | 2.6 | 9 |
| 67 | Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 2790-2797. | 2.4 | 8 |
| 68 | Effects of SNP variants in the $17\hat{I}^2$ -HSD2 and $17\hat{I}^2$ -HSD7 genes and $17\hat{I}^2$ -HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 192-198. | 2.5 | 8 |
| 69 | Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0134351. | 2.5 | 8 |
| 70 | MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. <i>Scientific Reports</i> , 2016, 6, 33153. | 3.3 | 8 |
| 71 | Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 2163-2174. | 0.9 | 8 |
| 72 | Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis. <i>Gene</i> , 2021, 793, 145747. | 2.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Prevalence of the CHEK2 R95* germline mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 19. | 1.5 | 6 |
| 74 | Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 228-235. | 2.5 | 6 |
| 75 | Introducing nano-scale quantitative polymerase chain reaction. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 923-926. | 2.1 | 5 |
| 76 | BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?. <i>Clinical Epigenetics</i> , 2018, 10, 128. | 4.1 | 5 |
| 77 | Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 23463. | 3.3 | 5 |
| 78 | Chemosensitivity and p53; new tricks by an old dog. <i>Breast Cancer Research</i> , 2012, 14, 325. | 5.0 | 4 |
| 79 | Impact of <i>MDM2</i> promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer. <i>Biomarkers</i> , 2021, 26, 302-308. | 1.9 | 4 |
| 80 | MDM2 SNP309 and risk of cervical cancer. <i>Tumor Biology</i> , 2014, 35, 6185-6186. | 1.8 | 3 |
| 81 | Promoter SNPs rs116896264 and rs73933062 form a distinct haplotype and are associated with galectin-4 overexpression in colorectal cancer. <i>Mutagenesis</i> , 2016, 31, 401-408. | 2.6 | 3 |
| 82 | The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2- Δ 5 in Breast Cancer Cells. <i>Translational Oncology</i> , 2017, 10, 806-817. | 3.7 | 3 |
| 83 | The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer. <i>PLoS ONE</i> , 2020, 15, e0225357. | 2.5 | 3 |
| 84 | Letter to the editor MDM2 SNP309 and risk of endometrial cancer. <i>Polish Journal of Pathology</i> , 2013, 1, 69-69. | 0.3 | 2 |
| 85 | <i>ramr</i> : an R/Bioconductor package for detection of rare aberrantly methylated regions. <i>Bioinformatics</i> , 2021, 38, 133-140. | 4.1 | 2 |
| 86 | NEW DOCTORIAL CANCER RESEARCH:Germline Genetic Alterations Affecting CDKN2A, MDM2, and CDKN1A in Melanoma and Breast Cancer Patients. <i>Critical Reviews in Oncogenesis</i> , 2007, 13, 261-263. | 0.4 | 1 |
| 87 | P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 2749-2749. | 5.1 | 1 |
| 88 | Genomic heterogeneity in primary breast cancer: Clinical implications.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11004-11004. | 1.6 | 1 |
| 89 | Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 555-555. | 1.6 | 1 |
| 90 | Constitutional <i>BRCA1</i> methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10509-10509. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Re: <i>Murine double minute 2</i> promoter SNP309 polymorphism and prostate cancer risk: a meta-analysis. <i>International Journal of Urology</i> , 2012, 19, 966-966. | 1.0 | 0 |
| 92 | MDM2 SNP309 and risk of endometrial cancer. <i>Tumor Biology</i> , 2014, 35, 7285-7286. | 1.8 | 0 |
| 93 | Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-18-P3-09-18. | 0.9 | 0 |
| 94 | Title is missing!. , 2020, 15, e0225357. | | 0 |
| 95 | Title is missing!. , 2020, 15, e0225357. | | 0 |
| 96 | Title is missing!. , 2020, 15, e0225357. | | 0 |
| 97 | Title is missing!. , 2020, 15, e0225357. | | 0 |